查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493315

美國多組體學市場規模、佔有率和趨勢分析報告：按產品/服務、按類型、按平台、按應用、按最終用途、細分市場預測，2024-2030 年

U.S. Multiomics Market Size, Share & Trends Analysis Report By Product & Service (Instruments, Consumables), By Type (Single-cell, Bulk), By Platform, By Application, By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

美國多組體學市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，美國多組體學市場規模將達到29億美元，2024年至2030年複合年成長率為15.55%。

市場開拓背後有多種因素，包括體學技術的進步、個人化藥物需求的增加、慢性病的傳播以及藥物發現和開發應用的增加。因此，預計在預測期內美國對多組體學的需求將會增加。

COVID-19 的爆發刺激了美國多組體學產業的進步，加速了研究，推動了診斷創新，並加強了精準醫療。它加速了藥物發現，促進了與生物庫的合作，並促進了多組體學與遠端醫療的整合。透過全面的體學分析，研究人員深入了解了 COVID-19 的發病機制，支持個人化醫療解決方案的開發並加強感染疾病控制工作。

此外，在人工智慧的進一步推動下，多組體學將透過整合基因組學、蛋白質組學和代謝體學的資料來實現生物醫學研究的現代化。人工智慧演算法分析複雜的組體學資料集，以揭示分子見解、識別生物標記並預測疾病結果。此次合作將加深我們對生物系統的理解，加速藥物發現並促進個人化醫療保健方法，從而推動生物醫學的轉型。例如，2023 年 5 月，Google雲端宣布推出兩款新的生命科學領域人工智慧主導解決方案，以加速生物技術、製藥和上市公司的藥物發現和精準醫療。標靶和先導物識別套件可幫助研究人員識別胺基酸功能並預測蛋白質結構，而多組學套件可快速分析和解釋基因組資料並幫助公司創建量身定做的治療方法。

然而，多組體學技術通常需要在設備、軟體和技術人員方面進行大量投資。資料分析和解釋的高昂初始成本和持續成本可能會限制採用並阻礙市場成長，特別是在小型研究機構和醫療機構。

美國多組體學市場報告亮點

  • 按產品/服務分類，該產品類別在 2023 年佔據市場最大的銷售佔有率。這是由於對能夠整合和分析不同組體學資料集的先進技術和工具的需求不斷成長。另一方面，預計服務業在預測期內將以最快的複合年成長率成長。
  • 按類型分類，批量多組體學市場在 2023 年佔據最大市場佔有率。批量多組體學的各種優勢歸因於其在該領域的主導地位。通常，批量體學對於系統地解釋個體層面的疾病發病機制和不同表現型至關重要。
  • 基於平台，基因組學領域在市場上佔據主導地位，2023 年收益佔有率為 39.8%。這是由於不斷成長的技術進步和對基因組研究活動的積極投資。同時，由於對個人化藥物的需求不斷增加，預計從 2024 年到 2030 年，代謝體學領域將以最快的複合年成長率成長。
  • 從應用來看，腫瘤學領域預計將在 2023 年以 40.7% 的收益佔有率主導市場，並在預測期內以最快的複合年成長率成長。癌症發生率的上升和多組體學在癌症中的廣泛應用預計將推動該領域的成長。
  • 按最終用途分類，學術和研究機構在該領域佔據主導地位，到 2023 年銷售佔有率將達到 49.0%。這是由於越來越多的研究和調查集中在基因組學、蛋白質組學、代謝體學和轉錄組學等多組體學方法。同時，預計 2024 年至 2030 年製藥和生技公司將以最快的複合年成長率成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章 產品和服務的業務分析

  • 產品和服務細分儀表板
  • 美國多組體學市場產品與服務波動分析
  • 2018-2030 年美國多組體學市場規模和趨勢分析（按產品和服務）
  • 產品
    • 2018-2030 年產品市場估計與預測
    • 裝置
    • 消耗品
    • 軟體
  • 服務
    • 2018-2030 年服務市場估計與預測

第5章 類型業務分析

  • 類型細分儀表板
  • 美國多組體學市場類型波動分析
  • 2018-2030 年美國多組體學市場規模與趨勢分析（按類型）
  • 單細胞多組體學
  • 批量多組體學

第6章 平台業務分析

  • 平台細分儀表板
  • 美國多組體學市場平台波動分析
  • 2018-2030 年美國多組體學市場規模與趨勢分析（按平台）
  • 基因組學
  • 轉錄組學
  • 蛋白質體學
  • 代謝體學
  • 綜合體學平台

第7章 應用業務分析

  • 使用細分儀表板
  • 美國多組體學市場應用波動分析
  • 2018-2030 年美國多組體學市場規模與趨勢分析（按應用）
  • 細胞生物學
  • 腫瘤學
  • 神經病學
  • 免疫學

第 8 章最終用途業務分析

  • 最終用途細分儀表板
  • 美國多組體學市場的最終用途變化分析
  • 2018-2030 年美國多組體學市場規模與趨勢分析（依最終用途）
  • 學術研究所
  • 製藥和生物技術公司
  • 其他

第9章 競爭格局

  • 公司分類
  • 策略規劃
  • 2023 年企業市場分析
  • 公司簡介/名單
    • BD
    • Thermo Fisher Scientific Inc.
    • Illumina, Inc
    • Danaher
    • PerkinElmer Inc.
    • Shimadzu Corporation
    • Bruker
    • QIAGEN
    • Agilent Technologies, Inc.
    • BGI
Product Code: GVR-4-68040-282-8

U.S. Multiomics Market Growth & Trends:

The U.S. multiomics market size is anticipated to reach USD 2.90 billion by 2030 and is projected to grow at a CAGR of 15.55% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth can be attributed to various factors such as advancements in omics technology, increasing demand for personalized medicines, growing prevalence of chronic diseases, and rising application in drug discovery & development. This has led to an anticipation of increased demand for multiomics in the U.S. over the forecast period.

The COVID-19 pandemic has stimulated advancements in the U.S. multiomics industry, accelerating research, driving diagnostic innovations, and enhancing precision medicine. It has expedited drug discovery, promoted biobanking collaborations, and facilitated the integration of multiomics into telemedicine. Through comprehensive omics analysis, researchers gained insights into COVID-19 pathogenesis, aiding in the development of personalized healthcare solutions and bolstering infectious disease management efforts.

Moreover, multiomics, which is further fueled by AI, modernizes biomedical research by integrating data from genomics, proteomics, and metabolomics. Artificial intelligence algorithms analyze complex omics datasets to uncover molecular insights, identify biomarkers, and predict disease outcomes. This collaboration enhances the understanding of biological systems, accelerates drug discovery, and facilitates personalized healthcare approaches, marking a transformative shift in biomedical sciences. For instance, in May 2023, Google Cloud introduced two novel AI-driven solutions in life sciences for expediting drug discovery and precision medicine for biotech firms, pharmaceutical companies, and public sector entities. The Target and Lead Identification Suite supports researchers in identifying amino acid functionalities and forecasting protein structures, while the Multiomics Suite fast-tracks genomic data analysis and interpretation, empowering companies to devise tailored treatments effectively.

However, multiomics technologies often require substantial investment in equipment, software, and skilled personnel. High initial costs and ongoing expenses for data analysis and interpretation may limit adoption, particularly among smaller research institutions and healthcare facilities, thus hampering the growth of the market.

U.S. Multiomics Market Report Highlights:

  • In terms of products & services, the product segment dominated the market in 2023 with the largest revenue share. This is due to the increasing demand for advanced technologies and tools for enabling the integration & analysis of diverse omics data sets. On the other hand, the services segment is anticipated to grow at the fastest CAGR over the forecast period.
  • Based on type, the bulk multiomics segment held the largest market share in 2023. The various advantages of bulk multiomics can be attributed to the segment's dominance. Typically, bulk multiomics is essential for systematically explaining disorder pathogenesis and different phenotypes at the individual level.
  • Based on platform, the genomics segment dominated the market in 2023 with a revenue share of 39.8%. This is attributed to the growing technological advancements and active investments in genomic research activities. On the other hand, the metabolomics segment is anticipated to grow at the fastest CAGR from 2024 to 2030, owing to the rising demand for personalized medicines.
  • In terms of application, the oncology segment dominated the market in 2023 with a revenue share of 40.7%, and it is expected to grow at the fastest CAGR over the forecast period. The rising incidence of cancer and the growing use of multiomics for cancer are anticipated to drive segment growth.
  • Based on end-use, academic & research institutes dominated the segment with a revenue share of 49.0% in 2023. This is attributed to the increasing studies and research focusing on multiomics approaches, including genomics, proteomics, metabolomics, and transcriptomics. On the other hand, pharmaceutical & biotechnology companies is anticipated to grow at the fastest CAGR from 2024 to 2030.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Product & Services Segment
    • 1.1.2. Type Segment
    • 1.1.3. Platform Segment
    • 1.1.4. Application Segment
    • 1.1.5. End-use Segment
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Primary Research
  • 1.5. Information or Data Analysis:
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objective

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. The increasing interest of researchers in the field of single-cell genomics
      • 3.2.1.2. Rising incidence of chronic diseases
      • 3.2.1.3. Technological advancements
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High initial costs
      • 3.2.2.2. Stringent government policies and regulations
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product & Services Business Analysis

  • 4.1. Product & Services Segment Dashboard
  • 4.2. U.S. Multiomics Market Product & Services Movement Analysis
  • 4.3. U.S. Multiomics Market Size & Trend Analysis, by Product & Services, 2018 to 2030 (USD Million)
  • 4.4. Product
    • 4.4.1. Product market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Instruments
      • 4.4.2.1. Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Consumables
      • 4.4.3.1. Consumables market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Software
      • 4.4.4.1. Software market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Type Business Analysis

  • 5.1. Type Segment Dashboard
  • 5.2. U.S. Multiomics Market Type Movement Analysis
  • 5.3. U.S. Multiomics Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Single-cell Multiomics
    • 5.4.1. Single-cell multiomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Bulk Multiomics
    • 5.5.1. Bulk multiomics market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Platform Business Analysis

  • 6.1. Platform Segment Dashboard
  • 6.2. U.S. Multiomics Market Platform Movement Analysis
  • 6.3. U.S. Multiomics Market Size & Trend Analysis, by Platform, 2018 to 2030 (USD Million)
  • 6.4. Genomics
    • 6.4.1. Genomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Transcriptomics
    • 6.5.1. Transcriptomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Proteomics
    • 6.6.1. Proteomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. Metabolomics
    • 6.7.1. Metabolomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8. Integrated Omics Platform
    • 6.8.1. Integrated omics platform market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

  • 7.1. Application Segment Dashboard
  • 7.2. U.S. Multiomics Market Application Movement Analysis
  • 7.3. U.S. Multiomics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 7.4. Cell Biology
    • 7.4.1. Cell biology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5. Oncology
    • 7.5.1. Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6. Neurology
    • 7.6.1. Neurology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7. Immunology
    • 7.7.1. Immunology market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. End-Use Business Analysis

  • 8.1. End-Use Segment Dashboard
  • 8.2. U.S. Multiomics Market End-Use Movement Analysis
  • 8.3. U.S. Multiomics Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
  • 8.4. Academic & Research Institutes
    • 8.4.1. Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5. Pharmaceutical & Biotechnology Companies
    • 8.5.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6. Others
    • 8.6.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2023
  • 9.4. Company Profiles/Listing
    • 9.4.1. BD
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Thermo Fisher Scientific Inc.
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Illumina, Inc
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Danaher
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. PerkinElmer Inc.
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Shimadzu Corporation
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Bruker
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. QIAGEN
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Agilent Technologies, Inc.
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. BGI
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. multiomics market, by product & services, 2018 - 2030 (USD Million)
  • Table 4 U.S. multiomics market, by type, 2018 - 2030 (USD Million)
  • Table 5 U.S. multiomics market, by platform, 2018 - 2030 (USD Million)
  • Table 6 U.S. multiomics market, by application, 2018 - 2030 (USD Million)
  • Table 7 U.S. multiomics market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 Key companies undergoing expansions
  • Table 9 Key companies undergoing acquisitions
  • Table 10 Key companies undergoing collaborations
  • Table 11 Key companies launching new products/services
  • Table 12 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 U.S. multiomics market: market outlook
  • Fig. 7 U.S. multiomics competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 U.S. multiomics market driver impact
  • Fig. 10 U.S. multiomics market restraint impact
  • Fig. 11 U.S. multiomics market: Product & services movement analysis
  • Fig. 12 U.S. multiomics market: Product & services outlook and key takeaways
  • Fig. 13 Products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Consumables market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Software market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. multiomics market: Type movement analysis
  • Fig. 19 U.S. multiomics market: Type outlook and key takeaways
  • Fig. 20 Single-cell multiomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Bulk multiomics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. multiomics market: Platform movement analysis
  • Fig. 23 U.S. multiomics market: Platform outlook and key takeaways
  • Fig. 24 Genomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Transcriptomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Proteomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Metabolomics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Integrated omics platform market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. multiomics market: Application movement analysis
  • Fig. 30 U.S. multiomics market: Application outlook and key takeaways
  • Fig. 31 Cell biology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Neurology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Immunology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. multiomics market: End-use movement analysis
  • Fig. 36 U.S. multiomics market: End-use outlook and key takeaways
  • Fig. 37 Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Market share of key market players - U.S. multiomics market